drugset / Trial / NCT01028027

Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

NCT01028027

Phase 3 Completed 357 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is to evaluate the safety and efficacy of loteprednol etabonate \[LE\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).

Timeline

Start
2009-10
Primary completion
2010-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 0.1 % Topical
Subject Loteprednol Etabonate Other / unclassified 0.5 % Topical
Comparator Tobramycin Small molecule 0.3 % Topical